NEW YORK ─ Dante Labs, Cambridge Cancer Genomics (CCG.ai), and Nonacus said on Monday that they have inked a collaboration agreement to build a high-throughput cancer sequencing and interpretation service for tumor profiling that enables improved patient management, treatment, and monitoring.
The firms said that the service will combine Dante Labs’ experience and capacity in delivering a sequencing service for solid tumor and cell-free circulating tumor DNA from liquid biopsies with Nonacus’ targeted pan-cancer NGS libraries and CCG.ai’s AI-based software platform, OncOS.